Home Biosimilar Antibodies Transmembrane Transporters CD markers Ocrelizumab (Anti-CD20)
For research use only. Not for use in humans.

Ocrelizumab (Anti-CD20)

Synonyms: null

Ocrelizumab (Anti-CD20) is a recombinant humanized monoclonal IgG1 antibody that selectively targets CD20 antigen present on B-cells. It is used to treat relapsing remitting multiple sclerosis. MW:145.5 KD.

Ocrelizumab (Anti-CD20)

1 Citation

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: Purity: 99% Protein concentration: 8.595mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Ocrelizumab (Anti-CD20) is a recombinant humanized monoclonal IgG1 antibody that selectively targets CD20 antigen present on B-cells. It is used to treat relapsing remitting multiple sclerosis. MW:145.5 KD.

Product Details

CAS No. 637334-45-3
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06688331 RECRUITING Presymptomatic Diabetes Type 1 (Stage 1); Diabetes Mellitus, Type I; Diabetes Mellitus, Type 1 PolTREG S.A. 2025-03-12 PHASE2
NCT06824701 ACTIVE_NOT_RECRUITING Drug: Zanubrutinib|Drug: Rituximab|Drug: Obinutuzumab Relapsed or Refractory B-cell Non-Hodgkin Lymphoma University of Utah 2025-09-12 PHASE1
NCT05285891 ACTIVE_NOT_RECRUITING Drug: Ocrelizumab|Drug: Placebo for Ocrelizumab Multiple Sclerosis National Institute of Allergy and Infectious Diseases (NIAID) 2023-02-07 PHASE4
NCT07189325 RECRUITING Drug: Platform therapies (Dimethyl Fumarate, Teriflunomide, Relapsing-Remitting Multiple Sclerosis (RRMS); Anti-CD20 Therapy University Hospital, Montpellier 2026-06-15 PHASE3
NCT06149286 RECRUITING Drug: Odronextamab|Drug: Lenalidomide|Drug: Rituximab Relapsed/Refractory Follicular Lymphoma; Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) Regeneron Pharmaceuticals 2023-12-28 PHASE3
NCT05758831 RECRUITING Drug: Perfusion of treatment Rituximab|Drug: Perfusion of tr Multiple Sclerosis; Relapsing-remitting Multiple Sclerosis Rennes University Hospital 2023-06-01 PHASE3

(data from https://clinicaltrials.gov, updated on 2026-07-17)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.